Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie, J&J's Imbruvica Has Rare, But Not Surprising Failure In DLBCL

Jul 12 2018

• By Mandy Jackson

Render illustration of Clinical Trial title on medical documents

Related Content

ASH In Review: Roche Refreshes Hematology Portfolio With Robust New Drugs

Dec 16 2017

Spate Of Late-Stage DLBCL Trial Failures Leaves Spoils Waiting

Aug 16 2016

AbbVie outdoes rumored J&J bid with $21bn Pharmacyclics buy

Mar 05 2015

AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica

Nov 01 2017

Related Companies

AbbVie Inc.

Johnson & Johnson

Bristol Myers Squibb Company

Johnson & Johnson

Roche Holding AG

Biogen, Inc.

Pharmacyclics, Inc.

AstraZeneca PLC

Additional Topics

Clinical Trials Market Intelligence Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window